AUG 12·SEC EDGARLow
Sohi Mohsen sold $957K of STE
Sohi Mohsen sold 4,058 shares of STERIS plc (STE) at $235.78 ($0.96M total) on 2026-08-12.
StockNYSE · US · USDHealthcare · Medical Devices
$STE
STERIS plc
Price · $STEvia TradingView
AI sentiment · 7d8 articles
- Bullish
- 4
- Neutral
- 4
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $957K 1 txs
Sohi Mohsen1× · $957K
10b5-1 share of filings0%
Top stories · $STEMore →
AUG 9·finance.yahoo.com
STERIS Q1 Earnings Call Highlights
STERIS (NYSE:STE) reported Q1 Healthcare capital equipment revenue up 1% and ending backlog at $444 million, while capital equipment orders rose 4%. Healthcare EBIT margin increased 60 bps to 24.8%. Life Sciences organic revenue grew 8% and EBIT margin fell to 42.1%. STERIS plans a $600 million North Carolina chemistry center, with FY2027 EPS guidance $11.10 to $11.30.
AUG 9·simplywall.st
STERIS (STE) Stock Faces Valuation Scrutiny After Margin Gains And Higher Capex
Simply Wall St reports that STERIS (STE) rose about 2.5% to $237.47 after its Q1 FY2027 results. Revenue was $1,492.7m (+7.3% YoY) and net income $200.1m (+12.8%), with EPS of $2.05. The article highlights higher margins, higher capex, and valuation concerns around a ~28.8x P/E and EPS guidance of $11.10 to $11.30.
STE sentiment & insider activity
Over the past 7 days, alphai's AI scored 8 news stories mentioning STE (STERIS plc). Coverage has skewed bullish: 4 bullish, 4 neutral, and 0 bearish.
Recent STE coverage spans earnings, financial news and corporate actions.
In the last 30 days, STE insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($957K). The most active reporter was Sohi Mohsen with 1 filing.
What's driving STE
This is a routine insider open-market sale with no 10b5-1 plan disclosed, but it does not by itself signal a fundamental change.
Guidance reaffirmation plus a large capex plan and restructuring charges can shift near-term FCF expectations and medium-term margin/capacity outlook.
Valuation scrutiny centers on whether STE’s margin gains can offset higher capex and weaker cash conversion, with execution risk through FY2029.
The disclosed capex and state support suggest incremental capacity expansion in STERIS’ chemistries manufacturing and distribution network.
The article signals a major US capacity expansion tied to rail-served logistics, which can support medium-term volume growth and supply-chain reliability.
alphai scores every news story that mentions STE with an AI model for sentiment and relevance, and aggregates insider trades from STERIS plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $STE
Score
Sohi Mohsen sold $957K of STE
Sohi Mohsen sold 4,058 shares of STERIS plc (STE) at $235.78 ($0.96M total) on 2026-08-12.
1 min readSTERIS Q1 Earnings Call Highlights
STERIS (NYSE:STE) reported Q1 Healthcare capital equipment revenue up 1% and ending backlog at $444 million, while capital equipment orders rose 4%. Healthcare EBIT margin increased 60 bps to 24.8%. Life Sciences organic revenue grew 8% and EBIT margin fell to 42.1%. STERIS plans a $600 million North Carolina chemistry center, with FY2027 EPS guidance $11.10 to $11.30.
4 min readSTERIS (STE) Stock Faces Valuation Scrutiny After Margin Gains And Higher Capex
Simply Wall St reports that STERIS (STE) rose about 2.5% to $237.47 after its Q1 FY2027 results. Revenue was $1,492.7m (+7.3% YoY) and net income $200.1m (+12.8%), with EPS of $2.05. The article highlights higher margins, higher capex, and valuation concerns around a ~28.8x P/E and EPS guidance of $11.10 to $11.30.
6 min readSTERIS Plans Sanford, North Carolina, Manufacturing Operations
STERIS plc plans a $600 million manufacturing, R&D and lab facility in Sanford, North Carolina, at Helix Innovation Park. The project is expected to create 335 jobs and serve as its Chemistries Manufacturing Center of Excellence. North Carolina approved a JDIG grant, potentially reimbursing up to $3.213 million over 12 years, tied to annual performance targets.
3 min readNorth Carolina Railroad Co., Norfolk Southern help land major medical manufacturing center
North Carolina Railroad Co. and Norfolk Southern are backing a $600 million STERIS Chemistries Manufacturing Center of Excellence in Sanford, N.C. NCRR will spend up to $600,000 on rail infrastructure, enabling at least 160 railcars annually by 2031. The project is expected to create 335+ jobs, with operations starting in 2-3 years, according to company releases.
3 min readSTERIS plc (STE): Submission of Matters to a Vote of Security Holders
STERIS plc (STE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001757898 0001757898 2026-07-31 2026-07-31 0001757898 us-gaap:CommonStockMember 2026-07-31 2026-07-31 0001757898 ste:STETwo700SeniorNotesDue2031Member 2026-07-31 2026-07-31 0001757898 ste:Two700SeniorNotesDue2051Member 2026-07-31 2026-07-31 UNITED STATES SECURITIES AND
2 min read
Democratic governors doing good things: 9 examples
The article is a political roundup of Democratic governors’ actions in several states. It highlights New Mexico Gov. Michelle Lujan Grisham on housing and ICE protections, New York Gov. Kathy Hochul on a data center moratorium and preschool, and North Carolina Gov. Josh Stein’s announcement that STERIS (NYSE: STE) will invest $600 million and create 335 jobs. It also cites Oregon Gov. Tina Kotek’s $10 million Regional Infrastructure Fund and a tariff impact analysis.
4 min read
SANFORD: Health care company to create 335 jobs
STERIS, a health care products and services company, will create 335 jobs in Lee County, North Carolina, and invest $600 million in a new 600,000-square-foot manufacturing and distribution center in Sanford, including R&D and a Center of Excellence for formulated chemistries. The state approved a 12-year JDIG grant, with potential reimbursement up to $3.213 million, and projects $1.8 billion in economic growth.
3 min read
STERIS (NYSE:STE) Posts Q2 CY2026 Sales In Line With Estimates
Steris (NYSE:STE) reported Q2 CY2026 sales of $1.49 billion, up 7.3% year on year and in line with Wall Street estimates. Non-GAAP adjusted EPS was $2.59, up from $2.34, beating consensus by 3.9%. Adjusted operating margin was 19.1% in Q2. Analysts expect revenue growth of 7.1% and full-year EPS to rise from $10.42 to $11.45.
4 min readSTERIS plc (STE): Results of Operations and Financial Condition
STERIS plc (STE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ste6302026ex991.htm EX-99.1 Document Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2027 First Quarter • Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6% • Fiscal 2027 first quarter as reported diluted EPS incre
6 min read